December 2, 2021 Chemomab Announces FDA Clearance of Its IND Application for CM-101, a First-In-Class CCL24 Neutralizing Antibody for the Treatment of Primary Sclerosing Cholangitis View Article
September 27, 2021 Chemomab Therapeutics Announces Collaboration with Leeds University to Further Elucidate the Role of CCL24 in Vascular Damage Associated with Systemic Sclerosis View Article
September 2, 2021 Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer View Article
June 23, 2021 Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III View Article
February 14, 2019 Anchiano Therapeutics Announces Pricing of $30.5 Million Initial Public Offering View Article
